Amgen Inc. (NASDAQ:AMGN) – Analysts at Gabelli reduced their FY2018 EPS estimates for Amgen in a research report issued to clients and investors on Wednesday. Gabelli analyst J. He now anticipates that the firm will post earnings per share of $13.00 for the year, down from their prior forecast of $13.05. Gabelli has a “Hold” rating on the stock. Gabelli also issued estimates for Amgen’s FY2020 earnings at $12.15 EPS.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, July 27th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.74 by $0.10. The firm had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.58 billion. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.57 EPS.
A number of other equities research analysts have also recently weighed in on AMGN. Leerink Swann restated a “hold” rating on shares of Amgen in a report on Saturday, September 17th. Vetr upgraded Amgen from a “sell” rating to a “hold” rating and set a $171.34 price target on the stock in a report on Wednesday, August 3rd. Credit Suisse Group AG set a $206.00 target price on Amgen and gave the company a “buy” rating in a report on Saturday, September 17th. JPMorgan Chase & Co. reiterated a “hold” rating on shares of Amgen in a report on Wednesday. Finally, Robert W. Baird reiterated an “outperform” rating and set a $157.00 target price on shares of Amgen in a report on Friday, August 26th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $185.06.
Amgen (NASDAQ:AMGN) traded up 0.82% during midday trading on Thursday, hitting $166.81. The company had a trading volume of 3,999,620 shares. The firm has a market cap of $124.83 billion, a price-to-earnings ratio of 17.07 and a beta of 0.87. The stock has a 50 day moving average of $171.68 and a 200 day moving average of $161.02. Amgen has a 52-week low of $138.06 and a 52-week high of $176.85.
The firm also recently announced a quarterly dividend, which was paid on Thursday, September 8th. Stockholders of record on Wednesday, August 17th were given a dividend of $1.00 per share. This represents a $4.00 dividend on an annualized basis and a dividend yield of 2.40%. The ex-dividend date was Monday, August 15th. Amgen’s payout ratio is 40.90%.
In related news, VP Annette Louise Such sold 3,000 shares of Amgen stock in a transaction dated Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total value of $523,770.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.20% of the company’s stock.
A number of institutional investors have recently bought and sold shares of AMGN. Kelman Lazarov Inc. purchased a new position in Amgen during the first quarter worth approximately $252,000. FirstMerit Bank N A Trustee increased its position in shares of Amgen by 5.3% in the first quarter. FirstMerit Bank N A Trustee now owns 32,630 shares of the medical research company’s stock worth $4,893,000 after buying an additional 1,632 shares during the last quarter. Private Trust Co. NA increased its position in shares of Amgen by 1.8% in the first quarter. Private Trust Co. NA now owns 3,236 shares of the medical research company’s stock worth $485,000 after buying an additional 58 shares during the last quarter. Sigma Planning Corp increased its position in shares of Amgen by 7.6% in the first quarter. Sigma Planning Corp now owns 6,278 shares of the medical research company’s stock worth $941,000 after buying an additional 442 shares during the last quarter. Finally, McQueen Ball & Associates Inc. increased its position in shares of Amgen by 1.7% in the first quarter. McQueen Ball & Associates Inc. now owns 10,642 shares of the medical research company’s stock worth $1,596,000 after buying an additional 182 shares during the last quarter. Institutional investors and hedge funds own 79.15% of the company’s stock.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.